CJC-1295 No DAC: Modified GRF 1-29
A synthetic GHRH analogue with ~30 minute half-life, designed for pulsatile growth hormone release and Ipamorelin combination.
Quick Reference
| Research Dosage | 100-300mcg per administration |
|---|---|
| Frequency | 1-3 times daily |
| Administration | Subcutaneous injection |
| Half-Life | ~30 minutes |
| Reconstitution | 2-3mL bacteriostatic water (acetic water can aid dissolution) |
| Storage | Refrigerate after reconstitution, use within 4-6 weeks |
CJC-1295 without DAC – also known as Mod GRF 1-29 or Modified GRF (1-29) – is a synthetic analogue of growth hormone releasing hormone (GHRH). It stimulates growth hormone release through the GHRH receptor while maintaining natural pulsatile release patterns.
The "No DAC" designation is critical: this version lacks the Drug Affinity Complex, giving it a ~30 minute half-life that produces discrete GH pulses. This contrasts with CJC-1295 with DAC, which has a 6-8 day half-life creating sustained GH elevation.
The No DAC version is specifically designed for combination with Ipamorelin – the "CJC + Ipa" stack that has become one of the most popular GH peptide protocols in research.
Research Applications
CJC-1295 No DAC is primarily studied for its effects on growth hormone secretion and the GH-IGF-1 axis. Published research has examined applications across multiple areas:
Growth Hormone Research
- GHRH receptor activation and signalling mechanisms
- Pulsatile GH release patterns and amplitude
- Synergy studies with GHRPs, particularly Ipamorelin
- GHRH analogue pharmacology and pharmacokinetics
- Comparison studies between pulsatile and sustained GH release
Body Composition Research
- Lean mass effects via GH elevation
- Fat metabolism and lipolysis stimulation
- Age-related GH decline (somatopause) interventions
- Metabolic rate and energy expenditure
IGF-1 Axis Research
- GH-stimulated IGF-1 elevation patterns
- GH-IGF-1 axis modulation and feedback mechanisms
- Tissue-specific IGF-1 responses to pulsatile GH
CJC-1295 No DAC vs With DAC: Critical Distinction
| Property | No DAC (Mod GRF 1-29) | With DAC |
|---|---|---|
| Also Called | Mod GRF 1-29 | DAC:GRF |
| Half-Life | ~30 minutes | 6-8 days |
| GH Pattern | Pulsatile (discrete pulses) | Sustained (continuous) |
| Dosing | Multiple daily | 1-2x weekly |
| Ipamorelin Combo | Ideal – coordinates timing | Less common |
| Physiological | Mimics natural patterns | Non-physiological |
Why Choose No DAC
- Pulsatile release mimics natural GH physiology
- Coordinates perfectly with Ipamorelin timing
- Avoids potential receptor desensitisation from sustained stimulation
- More controllable – effects do not persist for days
Dosage Information
Standard Research Dosages
Dosages commonly referenced in research literature range from 100-300mcg per administration, administered 1-3 times daily. The pre-sleep dose is considered most important as it aligns with the natural nocturnal GH surge.
Combination with Ipamorelin (CJC + Ipa Stack)
The CJC-1295 No DAC + Ipamorelin combination activates both GHRH and GHRP pathways simultaneously:
- CJC-1295 No DAC: Activates GHRH receptor – signals pituitary to release GH
- Ipamorelin: Activates ghrelin receptor – amplifies the release signal
Typical Combination Protocol
CJC-1295 No DAC: 100-300mcg
Ipamorelin: 100-300mcg
Administration: Together, 1-3 times daily (pre-sleep most common)
Timing Considerations
GH release is affected by blood glucose levels. Research protocols typically specify administration on an empty stomach (2+ hours after eating) or first thing in the morning. Food consumption, particularly carbohydrates, should be avoided for 30-60 minutes post-administration to avoid blunting the GH response.
Reconstitution Guide
Important: GHRH peptides can be slow to dissolve compared to other peptides.
Required Materials
- CJC-1295 No DAC lyophilised powder (5mg or 10mg vial)
- Bacteriostatic water (water containing 0.9% benzyl alcohol)
- Optional: Acetic water (0.6% acetic acid) to improve dissolution
- Sterile insulin syringe for reconstitution
- Alcohol swabs for sterile technique
Tips for Successful Reconstitution
- Allow both bacteriostatic water and peptide vial to reach room temperature (~1 hour)
- Consider using 50/50 bacteriostatic water and acetic water (0.6% acetic acid) – this significantly improves dissolution
- Draw 2-3mL into the syringe and add to vial, directing the stream down the inside wall
- Do not shake – allow to dissolve naturally (may take 5-10 minutes for GHRH peptides)
- Gentle swirling is acceptable if needed
- The solution should be clear with no visible particles
- Refrigerate at 2-8°C immediately after dissolution
Concentration Reference Table
| Vial Size | Water Added | Concentration | 100mcg Dose | 200mcg Dose |
|---|---|---|---|---|
| 5mg | 2mL | 2.5mg/mL | 4 units (0.04mL) | 8 units (0.08mL) |
| 5mg | 2.5mL | 2mg/mL | 5 units (0.05mL) | 10 units (0.1mL) |
| 10mg | 2mL | 5mg/mL | 2 units (0.02mL) | 4 units (0.04mL) |
| 10mg | 2.5mL | 4mg/mL | 2.5 units (0.025mL) | 5 units (0.05mL) |
Storage Guidelines
Lyophilised (Powder) Form
- Refrigeration (2-8°C) recommended for optimal stability
- Freezing (-20°C) extends stability for long-term storage
- Protect from light and moisture
- Keep vial sealed until ready for reconstitution
Reconstituted Solution
- Must be refrigerated at 2-8°C
- Stable for 4-6 weeks when stored correctly
- Do not freeze after reconstitution – freezing can damage the peptide structure
- Avoid repeated temperature fluctuations
- Use sterile technique when drawing doses to prevent contamination
- If solution becomes cloudy or contains particles, discard and reconstitute a fresh vial
CJC-1295 + Ipamorelin: The Synergistic Stack
The CJC-1295 No DAC + Ipamorelin combination has become one of the most studied GH peptide protocols due to the synergistic activation of two distinct receptor systems. Understanding why this combination works requires examining each peptide's mechanism:
CJC-1295 No DAC Mechanism (GHRH Pathway)
- Binds to GHRH receptors on pituitary somatotrophs
- Activates adenylate cyclase via G-protein coupling
- Increases intracellular cAMP, triggering GH release
- Functions as the "release signal" for stored GH
Ipamorelin Mechanism (Ghrelin/GHRP Pathway)
- Binds to ghrelin (GHS) receptors on pituitary
- Activates phospholipase C pathway
- Increases intracellular calcium
- Functions as an "amplifier" of GH release
Why They Work Together
The two pathways converge at different points in the GH release cascade. GHRH (via CJC-1295) primarily triggers cAMP-mediated release, while ghrelin receptor activation (via Ipamorelin) triggers calcium-mediated release. Activating both pathways simultaneously produces greater GH output than either alone – a true pharmacological synergy.
Additionally, both peptides have similar half-lives (~30 minutes for CJC-1295 No DAC, ~2 hours for Ipamorelin), allowing coordinated dosing and aligned peak effects.
A pre-blended CJC-1295 + Ipamorelin formulation is available for research convenience, providing accurate ratios and simplified reconstitution.
Frequently Asked Questions
Common questions about CJC-1295 No DAC research
What is Mod GRF 1-29?
Mod GRF 1-29 is another name for CJC-1295 without DAC. The name breakdown: "Mod" = Modified, "GRF" = Growth Releasing Factor (older name for GHRH), "1-29" = Amino acids 1-29 of the GHRH sequence. It is a synthetic GHRH analogue with four amino acid substitutions that extend the half-life from minutes to approximately 30 minutes.
What is the difference between CJC-1295 with DAC and without DAC?
Without DAC (Mod GRF 1-29): Half-life of ~30 minutes, produces pulsatile GH release (discrete bursts), requires multiple daily doses, and is ideal for Ipamorelin combination. With DAC: Half-life of 6-8 days, produces sustained GH elevation, requires only 1-2 weekly doses, and has different research applications. The No DAC version mimics natural GH physiology more closely.
Why is CJC-1295 No DAC combined with Ipamorelin?
They activate different receptor systems that work synergistically. CJC-1295 activates GHRH receptors (tells the pituitary to release GH), while Ipamorelin activates ghrelin receptors (amplifies the release signal). Combined activation may produce synergistic GH release exceeding either peptide alone. Their similar half-lives also allow coordinated dosing.
Is CJC-1295 No DAC the same as Sermorelin?
Both are GHRH analogues, but CJC-1295 No DAC has four amino acid modifications providing improved stability. CJC-1295 has a half-life of ~30 minutes versus ~10-20 minutes for Sermorelin. CJC-1295 resists enzymatic degradation better due to its D-Ala2 modification that prevents DPP-IV cleavage.
Why does CJC-1295 No DAC dissolve slowly?
GHRH peptides have chemical properties that can make dissolution slower than other peptides. Room temperature equilibration (allowing both peptide and water to reach room temperature for ~1 hour) and acidified water (50/50 bacteriostatic water and acetic water at 0.6% acetic acid) can significantly improve dissolution.
What is the best time to administer CJC-1295 No DAC?
Pre-sleep administration is most common in research protocols, as this aligns with the natural nocturnal GH pulse. When combined with Ipamorelin, both peptides are typically administered together. Some protocols include additional daytime doses, particularly morning administration on an empty stomach.
What is the molecular weight of CJC-1295 No DAC?
CJC-1295 No DAC has a molecular weight of 3367.9 Da (Daltons).
Why choose CJC-1295 No DAC over the DAC version?
The No DAC version offers several advantages: pulsatile release mimics natural GH physiology, coordinates perfectly with Ipamorelin timing, avoids potential receptor desensitisation from sustained stimulation, and provides more controllable effects that do not persist for days. However, the DAC version may be preferred for research requiring sustained GH elevation.
The Science: How CJC-1295 No DAC Works
The GHRH System
Growth hormone release from the pituitary is controlled by hypothalamic hormones:
- Stimulatory: GHRH (Growth Hormone Releasing Hormone)
- Inhibitory: Somatostatin
GHRH binds to GHRH receptors on pituitary somatotrophs (GH-producing cells), triggering both GH synthesis and release. The balance between GHRH and somatostatin creates the natural pulsatile GH pattern observed throughout the day.
Why Native GHRH Does Not Work
Natural GHRH(1-44) has a very short half-life (minutes) due to rapid enzymatic degradation by DPP-IV (dipeptidyl peptidase IV). This enzyme cleaves GHRH between positions 2 and 3, inactivating the hormone almost immediately. This makes native GHRH impractical for research applications.
CJC-1295 Modifications
CJC-1295 No DAC is GHRH(1-29) with four strategic amino acid substitutions designed to resist degradation:
| Position | Native | Modified | Purpose |
|---|---|---|---|
| 2 | Ala | D-Ala | Prevents DPP-IV cleavage |
| 8 | Asn | Gln | Prevents asparagine rearrangement |
| 15 | Gly | Ala | Enhances bioactivity |
| 27 | Met | Leu | Prevents methionine oxidation |
These modifications extend half-life from minutes to ~30 minutes while maintaining full GHRH receptor activity.
GHRH Receptor Activation Cascade
- CJC-1295 binds GHRH receptors on pituitary somatotrophs
- G-protein coupled receptor activation occurs
- Adenylate cyclase activation increases intracellular cAMP
- Protein kinase A (PKA) is activated
- GH release from storage granules is triggered
- Increased GH gene expression occurs with repeated stimulation
Pulsatile vs Sustained Release: Why It Matters
Natural Physiology: GH is released in pulses throughout the day, with the largest pulse occurring during deep sleep. This pulsatility carries biological information – both amplitude and frequency matter for downstream effects.
CJC-1295 No DAC (Pulsatile)
- ~30 minute half-life produces discrete pulses
- GH rises sharply, then returns toward baseline
- Each dose = one pulse
- Mimics natural pulsatile pattern
- Allows receptor recovery between pulses
CJC-1295 with DAC (Sustained)
- 6-8 day half-life from albumin binding
- Sustained GHRH receptor activation
- GH remains elevated continuously
- Non-physiological pattern
- Potential for receptor desensitisation
Technical Specifications
| Systematic Name | CJC-1295 without DAC |
|---|---|
| Other Names | Mod GRF 1-29, Modified GRF (1-29), ModGRF, GRF 1-29, CJC w/o DAC, Tetrasubstituted GRF(1-29) |
| Amino Acid Count | 29 |
| Sequence | Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2 |
| Molecular Formula | C152H252N44O42 |
| Molecular Weight | 3367.9 Da |
| CAS Number | 863288-34-0 |
| Appearance | White to off-white lyophilised powder |
| Solubility | Freely soluble in water and aqueous buffers |
| Purity (PurposeLabs) | ≥99% (HPLC verified) |
| Storage (Lyophilised) | -20°C long-term, 2-8°C short-term |
| Storage (Reconstituted) | 2-8°C, use within 4-6 weeks |
Quality: Australian University Testing
Why Peptide Quality Matters
The research peptide market contains products of highly variable quality. Independent testing of products from various suppliers has revealed significant issues:
- Purity levels as low as 50% in products claiming "99% purity"
- Incorrect amino acid sequences (entirely wrong peptides)
- Truncated sequences (missing amino acids)
- Bacterial endotoxin contamination
- Oxidised or degraded peptides with reduced activity
Our Testing Protocol
Every batch of CJC-1295 No DAC from PurposeLabs undergoes comprehensive testing at a leading proteomics laboratory based at an Australian university in Sydney – one of Australia's premier analytical facilities.
Confirms purity levels of ≥99%, identifies any impurities or degradation products.
Verifies exact molecular weight, confirms correct amino acid sequence.
Determines actual peptide content versus salt, moisture, and counter-ions.
Why Australian University Testing?
Our testing partner is an established, verifiable proteomics facility at a major Australian university, with published research credentials, transparent methodology, and no commercial conflict of interest. This contrasts with overseas "certificates of analysis" from unknown or unverifiable laboratories.
Shop CJC-1295 No DAC
Australian university tested. 99%+ purity verified by HPLC and mass spectrometry. Fast shipping from Sydney.
| Product | Size | Price |
|---|
References
Key studies for researchers seeking primary literature:
- Alba M, et al. "Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse." American Journal of Physiology, 2006.
- Ionescu M, Bhopale GM. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295." Journal of Clinical Endocrinology & Metabolism, 2006.
- Teichman SL, et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." Journal of Clinical Endocrinology & Metabolism, 2006.
- Jetton TL, et al. "Growth hormone-releasing hormone receptor mRNA expression in hypothalamus and pituitary." Endocrinology, 1994.
- Frohman LA, Kineman RD. "Growth hormone-releasing hormone and pituitary development, hyperplasia and tumorigenesis." Trends in Endocrinology & Metabolism, 2002.
Disclaimer
All products sold by PurposeLabs are intended for laboratory and research use only. They are not intended for human or animal consumption. The information provided is for educational purposes only and should not be construed as medical advice. Consult with qualified healthcare professionals for any health-related decisions.
CJC-1295 No DAC is not approved by the TGA for therapeutic use in Australia. Products are sold strictly for research purposes in accordance with Australian regulations.